It was only the day after Christmas when I mentioned that Tekmira (TKMR) was a name that investors should think about investigating as a potentially cheaper play on RNA interference (RNAi) than better-known representatives of the class like Alnylam Pharmaceuticals (ALNY) and Isis Pharmaceuticals (ISIS). The stock had done pretty well since then (up about 20% in two weeks), but news of a deal with Monsanto (MON) gave another boost to the shares.
Now I'm starting to wonder if things are getting a little too crazy in RNAi-land. Alnylam was up very strongly on news of its partnership with Sanofi (SNY) and Tekmira too...
Only subscribers can access this article, which is part of the PRO research library covering 3,555 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: